Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia

Nachrichtenquelle: Business Wire (engl.)
29.05.2020, 14:00  |  107   |   |   

Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigational anti-CD47 monoclonal antibody, in combination with azacitidine in previously untreated patients with higher-risk myelodysplastic syndrome (MDS) and previously untreated patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, including patients with TP53-mutant AML, a high unmet need population. Results continue to support the clinical activity of magrolimab and azacitidine. The data were presented during an oral session at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29-31 (Abstract #7057).

At the time of the data cut-off, 68 patients had been treated with magrolimab plus azacitidine, including 39 patients with previously untreated higher-risk MDS and 29 patients with previously untreated AML. Of 33 MDS patients who were evaluable for efficacy, 91 percent (n=30/33) achieved an objective response (response assessments per 2006 IWG MDS criteria) including 42 percent (n=14/33) with a complete response (CR). Responses to magrolimab and azacitidine also deepened over time, as the CR rate with at least six months of follow-up was 56 percent in MDS patients.

In AML, 64 percent (n=16/25) of patients evaluable for efficacy achieved an objective response (response assessments per 2017 AML ELN criteria), including 56 percent (n=14/25) with a CR or a CR with incomplete blood count recovery (CRi). Notably in TP53-mutant AML (n=12), a treatment refractory and poor prognosis population, 75 percent achieved a CR or CRi.

Median duration of response and median overall survival have not yet been reached in MDS, AML or TP53-mutant AML, with a median follow-up of 5.8 (range: 2.0-15.0 months), 9.4 (range: 1.9-16.9 months) and 8.8 months (range: 1.9-16.9 months), respectively.

The safety profile of the combination of magrolimab plus azacitidine was generally consistent with prior reports with no maximum tolerated dose reached. Common all-grade treatment-related adverse events (AEs) among 68 patients with MDS or AML were anemia (38 percent), fatigue (21 percent), neutropenia (19 percent), thrombocytopenia (18 percent) and infusion reaction (16 percent). Treatment-related febrile neutropenia occurred in 1.5 percent of patients. Only one patient (1.5 percent) discontinued the trial due to a treatment-related AE.

Seite 1 von 4
Gilead Sciences Aktie jetzt ab 0€ handeln - auf Smartbroker.de

Diesen Artikel teilen

Diskussion: GILEAD SCIENCES 885823

Diskussion: Börsenexperte ist sicher: „Am Montag geht es abwärts für Gilead Sciences!“ – das ist der Grund!
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
EuroTwitterLeu


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel